Exploratory investigation of the anti-inflammatory effects of RNase A-treated Enterococcus faecalis strain EC-12

Biosci Biotechnol Biochem. 2019 Jul;83(7):1343-1353. doi: 10.1080/09168451.2019.1608805. Epub 2019 Apr 30.

Abstract

We previously reported that the major component of Enterococcus faecalis strain EC-12 (EC-12) inducing production of Interleukin (IL)-12 in mouse/human immune cells was its own RNA. This study aimed to investigate if RNase A-treated EC-12 could also produce IL-10 and to evaluate the possible effects of IL-10 produced by RNase A-treated EC-12. Three experiments were conducted: (1) Assessment of the effect of RNase A-treated EC-12 on transcriptome profiles and biological pathways in human peripheral blood mononuclear cells; (2) Determination of cytokine concentration in its culture supernatants; and (3) Supplementation of RNase A-treated EC-12 (RN) to mice with dextran sodium sulfate-induced colitis. Treatment of EC-12 with RNase A inhibited inflammatory response including the potency to induce IL-12 production, while it did not affect IL-10 production (Experiment 1 and 2). Colitis symptoms were milder in RN than in PBS-supplemented controls (Experiment 3). RNase A-treated EC-12 likely became an anti-inflammatory agent primarily inducing IL-10 production.

Keywords: Lactic acid bacteria; anti-inflammatory effect; bacterial RNA; colitis; mouse.

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / pharmacology*
  • Culture Media
  • Dextran Sulfate / adverse effects
  • Enterococcus faecalis / drug effects*
  • Humans
  • Interleukin-10 / biosynthesis
  • Mice
  • Ribonuclease, Pancreatic / pharmacology*

Substances

  • Anti-Inflammatory Agents
  • Culture Media
  • IL10 protein, human
  • Interleukin-10
  • Dextran Sulfate
  • Ribonuclease, Pancreatic